NEW! Storing Primary Series and Boosters
In order to continue offering primary series vaccines in addition to bivalent boosters, providers will need to keep multiple COVID-19 vaccine products in their inventory throughout the fall. CDC recommends providers offer simultaneous administration of all age-appropriate doses of vaccines for children, adolescents, and adults for whom no contraindications exist at the time of the healthcare visit.
Providers may need to make space for bivalent boosters:
- Reminder: monovalent mRNA COVID-19 vaccines are no longer authorized as a booster dose for individuals 12 years of age and older.
- Lower demand for primary series doses: less than 10% of adults have not received a single dose of COVID 19 vaccine.
- Higher demand for bivalent boosters: roughly 215 million people aged 12 years and older are eligible.
To better maintain vaccine storage space, providers are encouraged to:
- Assess storage space to determine freezer and refrigerator capacity before placing orders for vaccine, considering anticipated pediatric booster inventory as appropriate.
- Check expiry dates. Dispose of expired vaccine according to state and local regulations.
- Reduce vaccine ordering, reduce inventory, and place orders on an “as-needed” basis. In most instances, COVID-19 vaccine orders can be delivered within 24-48 hours.
- Zero out old inventory in Vaccines.gov and ensure the publicly posted amount reflects actual inventory on hand. This will help to reduce confusion and assist the public in identifying a location where they can receive a vaccine.
NEW! Transition from OKTA Authentication to CDC-supported SAMS
ATTENTION TIBERIUS USERS! In support of CDC’s initiative to move towards a consolidated authentication platform for systems that are leveraged by our external partners, user authentication is transitioning from OKTA to the CDC-supported Secure Access Management Services (SAMS) authentication platform. Upon completion of the transition, all users will be required to authenticate using SAMS.
This migration will occur between November 7-30, 2022. Users who do not currently have active SAMS accounts will be required to obtain one prior to November 7, 2022, to ensure no disruption to access occurs.
Impacted users will receive a notification from the SAMS team in early October to guide you through this process. Please monitor your e-mail for this notification. In the coming weeks, you will receive additional information about these and other critical dates. In the interim, if you have questions regarding the transition, please email Tiberius-help@cdc.gov, with the subject line “OKTA Authentication Transition to SAMS.”
REMINDER: Webinar links
Check out these links from our September 27th COVID-19 Provider Webinar.
COVID-19 Updates:
COVID-19 Vaccine Product Ordering (VAOS):
Resource slides:
Survey:
REMINDER: Monovalent Vaccine Threshold Top-offs
Thresholds for primary series (monovalent) vaccines will now receive a top-off on a monthly cadence for all channels.
- Beginning in October, the monthly thresholds will be posted on the first Monday of each month.
- No awardee will lose available doses to order. Monthly thresholds will account for the previously established biweekly top lines.
- All channels will have increased flexibility to place orders throughout the month based on the same amount of monovalent vaccine.
- Out of cycle requests for monovalent vaccines are still possible.
REMINDER: Webinar Live Q&A Five
The 9/20/22 webinar offered us even more insight into the Bivalent vaccine and processes for ordering and storage and handling. Our special guest, Dr. Pam Gobina, from Moderna, provided excellent guidance and helpful answers regarding Moderna Vaccines. Here is a snapshot of some of the questions we pulled from our Q&A section:
Q: I ordered the bivalent vaccine last month and have not received any doses. When shall I expect it? Is there a delay?
A: Hello, yes there is a delay in processing approved Moderna Bivalent vaccine orders as we wait to be allocated more of that vaccine type.
Q: Where can we print out information on Bivalent for patient/parents?
A: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines
Q: Can you share a link that will provide us the extension dates for the expiration date for the Pfizer vaccine?
A: https://lotexpiry.cvdvaccine.com/Pfizer
Q: When will the Fact sheet for adults be translated to Spanish?
A: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines
All of the fact sheets are already available in multiple languages and can be reached by clicking on each of the manufacturers on this page.
Q: Can you distinctly summarize the difference between Comirnaty and the Novavax?
A: https://www.dshs.texas.gov/immunize/covid19/Texas-Provider-Webinar-080222.pdf Dr. Rai has covered this on a previous webinar and the information can be reviewed on the link above. The information starts on slide 12/46
NEW! Provider Tip! Regulatory Terminology for COVID-19 Vaccines
Active immunity: The production of antibodies against a specific disease by the immune system. Active immunity can be acquired in two ways, either by contracting the disease or through vaccination. Active immunity is usually permanent, meaning an individual is protected from the disease for the duration of their lives.
Booster shots: Additional doses of a vaccine needed periodically to “boost” the immune system. For example, the tetanus and diphtheria (Td) vaccine which is recommended for adults every ten years.
Vaccine: A suspension of live (usually attenuated) or inactivated microorganisms (e.g. bacteria or viruses) or fractions thereof administered to induce immunity and prevent infectious diseases and their sequelae. Some vaccines contain highly defined antigens (e.g., the polysaccharide of Haemophilus influenzae type b or the surface antigen of hepatitis B); others have antigens that are complex or incompletely defined (e.g. Bordetella pertussis antigens or live attenuated viruses).
For more information, visit Clinical Guidance for COVID-19 Vaccination | CDC.
|
